Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT7U1O)

• Drug Name: PMID28460551-Compound-6 Drug Info
• Cross-matching ID: TTD Drug ID: DMT7U1O

Molecule-Related Drug Atlas

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[2]
AZD5363	DM9SKW8	Triple negative breast cancer	2C60-2C65	Phase 3	[2]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[2]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[3]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[4]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[5]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[6]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[7]
Trametinib + 2141795	DMYP7TO	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[2]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[3]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[8]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[2]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[2]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[10]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[11]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[12]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[1]

References

• [1] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [4] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [7] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [8] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [9] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [13] Clinical pipeline report, company report or official report of Turning Point Therapeutics.